Gilteritinib is an FLT3 inhibitor targeting specific gene mutations, primarily used to treat relapsed or refractory acute myeloid leukemia (AML). Its price varies depending on region, health insurance policies, and purchase channels; it must be used as directed by a doctor.
Price Range
Market prices are typically affected by hospitals, pharmacies, or charitable assistance programs. In the US, the monthly cost is approximately $30,000 to $40,000 (before insurance coverage). Some countries have reduced out-of-pocket expenses through health insurance negotiations; patients need to assess their actual expenses based on local policies.
Health Insurance and Reimbursement
In some regions, it is included in the health insurance catalog, but only if specific indications are met (such as carrying an FLT3 mutation and being assessed by a doctor for its necessity). Reimbursement rates vary by region; it is recommended to consult the hospital or health insurance department.
In areas not covered by health insurance, patients can apply for cost reductions through patient assistance programs, requiring documentation such as a diagnosis certificate and proof of financial situation.
Precautions for Use
Gilteritinib is a prescription drug and requires a prescription from a hematologist. It cannot be purchased or its dosage adjusted independently.
During treatment, regular monitoring of blood counts, liver function, and cardiac function is necessary. Any side effects (such as dizziness, diarrhea, and decreased blood oxygen levels) should be reported promptly.
Interactions with other medications (such as anticoagulants and immunosuppressants) are possible; please inform your doctor of all medications you are currently using.
Acquisition Channels
It is recommended to purchase medications from reputable hospitals or authorized pharmacies to avoid the risks associated with unofficial channels. When purchasing medications overseas, verify local regulations and the legality of the medication, and be aware of the impact of transportation and storage conditions on efficacy.
